A multiple drug regimen consisting of trandolapril, verathan the decrease observed for the TV combination, which was significantly (P = 0.001) greater than the pamil and hydrochlorothiazide (HCTZ) were sequentially added in an open-label evaluation of patients with sevdecrease observed for trandolapril monotherapy. Clinical responder rates were 44.8%, 56% and 77.7% for tranere hypertension. Ninety patients (58 white and 32 black patients) were titrated on one or more drugs and foldolapril monotherapy, trandolapril + verapamil combination therapy and triple therapy, respectively. Black lowed for a 19-week maintenance period. Statistically significant (P = 0.001) mean (± s.d.) decreases in supine and white patients had similar response rates, but black patients appeared to benefit more from the addition of diastolic blood pressure (DBP) were 9.0 (±9.3) mm Hg for trandolapril, 13.9 (±11.0) mm Hg for the trandolapril HCTZ; 20% of black patients achieved a post-treatment supine DBP Ͻ90 mm Hg compared to 12.8% of white + verapamil (TV) combination, and 19.0 (±12.3) mm Hg when hydrochlorothiazide was added to the combipatients. This study demonstrates that the addition of verapamil to trandolapril has an additive effect on BP nation. The decrease in BP observed on TV combination therapy plus HCTZ was significantly (P = 0.001) greater that is maintained throughout the day.
Introduction mil are similar. 7 Hence, results for black and white The physician today has a wide range of choices for patients are reported separately. the treatment of severe or resistant hypertension. The most frequently employed regimen has con-
Patients and methods
sisted of a diuretic, a sympatholytic agent, and a peripheral vasodilator.
1 But often this regimen does not Study design reduce blood pressure (BP) to acceptable levels or
This was an open-label, multicenter study to evaluleads to untoward side effects that result in disconate the safety and efficacy of trandolapril monothertinuation of the drug regimen by the patient. Thus, apy (2 mg, 4 mg, or 8 mg) and trandolapril in combithe ideal combination therapy should not only offer nation with slow release verapamil (180 mg) in synergistic antihypertensive effects, but also an patients with severe hypertension. The study conacceptable side effect profile. Recent publications sisted of a 3-to 14-day single-blind, placebo run-in have shown that when angiotensin-converting period, a 5-week, open-label dose-titration period, enzyme (ACE) inhibitors are combined with calcium and a 19-week maintenance period. A diagram of the channel blockers, the antihypertensive properties of study design is presented as Figure 1 . the combination have been impressive. [1] [2] [3] This paper reports the results of an evaluation of the safety and efficacy of the non-sulfhydryl ACEPatient population inhibitor trandolapril in combination with the calPatients could be enrolled in the study if they were cium antagonist verapamil in the treatment of between 21 and 70 years of age and had documented patients with severe hypertension. Trandolapril is severe hypertension (supine diastolic BP: 115 to 135 a prodrug which is rapidly hydrolyzed to its active mm Hg). Patients were excluded from enrollment if diacid metabolite, trandolaprilat. Previous clinical they had a cerebrovascular accident, convulsive distrials have demonstrated that black hypertensives do order, or hypertensive encephalopathy within the not respond as well to ACE inhibitors as white previous year; experienced a myocardial infarction within 3 months of the study, or had severe cardiac abnormalities, ie, congestive heart failure (CHF), hematological, or other metabolic abnormalities that administered higher doses of trandolapril than the white patients.
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could interfere with study drug absorption, metabolism, or excretion; had a history of drug abuse or The titration period began with the administration of a low dose of trandolapril, 2 mg qAM in the case addiction. Patients were also excluded if they required the concomitant use of other antihypertenof the white patients and 4 mg qAM in the case of the black patients. If adequate control of BP was not sives, digitalis glycosides, antiarrhythmics, antidepressant drugs, central nervous system stimulants achieved after 1 week, the dose of trandolapril was doubled for both white and black patients. BP was and depressants, chronic non-steroidal antiinflammatory drugs and analgesics, as well as any considered adequately controlled if supine DBP was р90 mm Hg. If after 2 weeks at the high dose of tranmedication that could elevate BP.
The protocol was approved by the appropriate dolapril, the patient's BP was still not adequately controlled, 180 mg qAM of the calcium channel institutional review committee and all patients gave written informed consent.
blocker verapamil was added. The daily dose of verapamil remained constant for the duration of the study. If a satisfactory response was not achieved Study procedures after 2 weeks of combined trandolapril plus verapamil therapy, the investigator could add 12.5 mg to At the initial visit prior to entry into the study, BP 25 mg of hydrochlorothiazide (HCTZ) or disconwas recorded in both arms. The arm with the highest tinue the patient from the study. sitting diastolic BP (DBP) was used for all subAt the principal investigator's discretion, patients sequent measurements throughout the study.
could be titrated more rapidly than indicated in the Patients who had been newly diagnosed or who had protocol to achieve faster BP control. Patients exhibbeen previously treated for severe hypertension, disiting a satisfactory response to either trandolapril or continued all antihypertensive medications and to trandolapril/verapamil combined therapy (with entered into a single-blind, placebo run-in period of or without HCTZ) at the completion of the doseat least 3 days but no longer than 14 days duration. titration period, continued to receive this therapy During the run-in period, patients were adminisduring the 19-week maintenance period. tered placebo once a day. At the end of the placebo Patient visits were scheduled every week during run-in period, patients with documented severe the 5-week dose-titration period, and at weeks 1, 3, hypertension advanced into a 5-week, open-label, 7, 9, 11, 15 , and 19 of the 19-week maintenance perdose-titration period. Qualifying DBP of between iod. At each visit, a physical examination was per-115 and 135 mm Hg was determined as the mean of formed, vital signs and BP were measured, comthree consecutive supine DBP measurements taken pliance was evaluated, and the patient was 2 min apart. In order to be advanced into the dosequestioned about the occurrence of adverse reactitration period, qualifying BP had to be docutions. The patient's cardiac status was monitored mented on the last visit of the placebo run-in period.
periodically throughout the study by 12-lead ECG. The first dose of trandolapril could be administered Routine clinical laboratory evaluations were also immediately after severe hypertension was docuperformed. mented at the time points indicated above. All sub-BP measurements were trough readings taken sequent doses were administered between 08.00 and immediately prior to the day's administration of 10.00 hours for the duration of the study.
scheduled study drug dose. At each study visit, after Since it has been reported that black patients do having the patient rest in a supine position for a not respond as well to ACE inhibitors as white patients, the black patients in this study were minimum of 10 min, systolic/diastolic BP and heart rate were measured. Standing BP measurements bination therapy with trandolapril and verapamil during the study. were also made, but are not reported here.
Seventy-one patients (79%) were titrated to combination therapy plus HCTZ by the completion of Measures of efficacy the study. Equal percentages of white and black patients, 62% and 63%, respectively, were titrated The primary measure of efficacy was mean change in trough supine DBP from baseline to post-treatto the highest doses of TV combination therapy plus HCTZ. ment. Baseline was considered the last BP measurement taken prior to the first open-label dose. PostForty-one patients (46%) discontinued therapy before the end of the 19-week maintenance period: treatment was the last trough BP measurement on a particular treatment.
11 during monotherapy (T), five during combination therapy (TV), and 25 during combination therapy In addition to evaluating the mean change in supine DBP, patients meeting the definition of plus hydrochlorothiazide (TV/HCTZ). 'responder' were tabulated. For the purpose of this study, a responder was defined as a patient whose BP response post-treatment trough supine DBP was Ͻ90 mm Hg, or who had at least a 10 mm Hg decrease in supine Eighty-seven of the 90 patients enrolled in the study DBP from baseline to post-treatment.
were included in the analysis of BP. The three patients that were excluded did not have appropriate post-treatment trough BP measurements.
Statistical analysis
Trandolapril monotherapy significantly (P Ͻ 0.01) Summary statistics were tabulated for demographics decreased supine DBP in this population of severely and baseline supine BPs. Counts and percentages of hypertensive patients ( Table 2 ). The decrease (± s.d.) patients with adverse events were tabulated. Mean in DBP (−9.0 mm Hg, ±9.3) that was observed followchanges from baseline to post-treatment supine BP ing trandolapril monotherapy was enhanced by the were tested for significance at the two-tailed 0.05 addition of verapamil, resulting in a decrease of 13.9 level using paired t-tests.
± 11.0 mm Hg following administration of TV combination therapy (P Ͻ 0.01). Patients who went on to receive TV combination therapy plus HCTZ had
Results
an overall mean decrease in supine DBP of 19 ± 12.3 Patient characteristics mm Hg (P Ͻ 0.01). Significant mean decreases in BP were observed for both black and white patients. Ninety patients with severe hypertension were enrolled at 11 study centers. Sixty-three patients However, white patients had a greater mean decrease in BP on trandolapril monotherapy com-(70%) were male and 27 were female. Patients had a mean age of 51.0 ± 11.1 years (range: 24 -71 years).
pared to black patients. The effects on systolic BP (SBP) paralleled those of DBP. Fifty-eight patients (64%) were white and 32 (36%) were black. Demographic and baseline character-
The decrease in BP observed on TV combination therapy plus HCTZ was significantly (P = 0.001) istics are summarized by treatment: trandolapril monotherapy (T), trandolapril verapamil combigreater than the decrease observed for the TV combination, which was significantly (P = 0.001) greater nation therapy (TV), and combination therapy with hydrochlorothiazide added (TV/HCTZ) in Table 1. than the decrease observed for trandolapril monotherapy. The three treatment groups were comparable with regard to baseline characteristics. Black and white
As can be seen in Table 2 , the per cent of patients characterized as 'responders' increased by 11% patients also had similar baseline characteristics with the exception of weight. The white patients when trandolapril was administered in combination with verapamil. The addition of HCTZ to the TV were an average 12 pounds heavier than the black patients.
combination resulted in a 22% increase in responder rate to 77%. The patients had an average history of hypertension of 12 years and the average patient had preAlthough black and white patients had similar response rates, black patients appeared to benefit viously received 2.4 (range: 0-7) antihypertensive drugs.
more when HCTZ was added to TV combination therapy. The percentage of patients who achieved a Seventy-five patients (83%) were titrated to com- Reduction in diastolic BP of у10 mm Hg or Ͻ90 mm Hg. T = trandolapril; TV = trandolapril/verapamil; HCTZ = hydrochlorothiazide. *P = 0.001 compared to baseline; †PϽ0.01, ‡P = 0.001 compared to monotherapy; ȿP = 0.001 compared to TV combination therapy.
post-treatment DBP Ͻ90 mm Hg reached a therapy (parasthesia face/scalp, cough), and two patients on combination therapy plus HCTZ (chest maximum of 12.8% for white patients compared to 20% for black patients on TV combination therapy pain, impotence). An additional 32 patients discontinued the study plus HCTZ.
Heart rate as determined by supine pulse before completion. Twenty-one patients discontinued due to an unsatisfactory therapeutic measurements was not affected by the addition of verapamil to trandolapril.
response, seven patients discontinued due to failure to follow the appointment schedule, two patients refused further therapy, and two patients moved out Adverse reactions of the area. Clinical laboratory parameters, including glucose, Thirty-six of 90 patients (40%) who received trandolapril alone, 27 of 78 patients (35%) who received potassium, and cholesterol, were not adversely affected by any study medication or combination trandolapril in combination with verapamil, and 35 of 73 patients (48%) who received combination thertreatment. apy plus HCTZ experienced adverse reactions during the open label phase of the study. The most freDiscussion quently reported adverse reactions are presented in Trandolapril monotherapy, administered once Table 3. daily, produced statistically significant decreases in Two patients had hypotension reported as an supine DBP in this population of severely hypertenadverse reaction after receiving TV combination sive patients. The response of the black hypertentherapy (8/180 mg). Both patients went on to comsives to trandolapril is consistent with previously plete the protocol, one after a reduction in trandolapublished reports that indicate that black patients pril dose to 4 mg.
respond less well to ACE inhibitors than white Nine patients discontinued treatment because of patients, an effect that may be dose-related. 6, 8 adverse reactions: five on monotherapy (headache, Once a day dosing with trandolapril in combinausea, fatigue, excessive perspiration, vomiting, nation with verapamil produced significant decheadache, dizziness, dyspnea, neuro-orthopedic reases in supine DBP beyond the decreases prosymptoms, chest pressure), two on combination duced by trandolapril alone. The combination was equally effective in lowering BP in black and white patients with mild to moderate hypertension, the
